oral mini pulse
Small molecule
oral mini pulse is one of 35 small molecule programs targeting Vitiligo. It is currently in development.
1
Indications
3
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
103 competitors in Vitiligo
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Opzelura
PfizerPhase 3
Prograf
VVeloxis Pharmaceuticals
Phase 3
Povorcitinib
IncytePhase 3
Olumiant
Eli LillyPhase 2
Saphnelo
AstraZenecaPhase 2
Kenalog
BBassett Healthcare
Phase 2
Glucophage
Boehringer IngelheimPhase 2
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Vitiligo3 trials
The Value of Adding Mini-oral Pulse Steroid Therapy in Preventing Peri-lesional Halo Post Non-cultured Epidermal Cell Suspension (NCES) in Cases With Stable Segmental and Non-acral Vitiligo.
Not yet recruiting·—·Phase 4·NCT07472816·60 enrolled
T Central Memory Cells in Early Localized Non-Segmental Vitiligo
Completed·—·N/A·NCT05706636·22 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for oral mini pulse. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- SSouth Valley University